X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
German Remedies: Impressive results, attractive valuation - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  
  • Home
  • Outlook Arena
  • May 27, 2000 - German Remedies: Impressive results, attractive valuation

German Remedies: Impressive results, attractive valuation

May 27, 2000

German Remedies (GRL) has outpaced the domestic formulation growth of 9.8% and reported a 19% growth in net profit on the back of an 11.7% growth in the topline.

(Rs m) FY99 FY00 Change
Sales 1,999 2,232 11.7%
Other Income 28 29 1.2%
Expenditure 1,589 1,773 11.6%
Operating Profit (EBDIT) 410 459 12.0%
Operating Profit Margin (%) 20.5% 20.6%  
Interest 18 14 -23.6%
Depreciation 48 64 31.4%
Profit before Tax 372 411 10.3%
Other Adjustments   (7)  
Tax 100 80 -20.0%
Profit after Tax/(Loss) 272 324 19.0%
Net profit margin (%) 13.6% 14.5%  
Earnings per share (Rs) 33 39  

GRL is owned by a group of German drug companies Boehringer Ingelheim, Asta Medica, Schering, Beecham Wolfing, Heller Vernog and Chemiework. The highest shareholding is that of Asta Medica which currently owns over 20% of the company's equity. Asta Medica specialises in oncology (anti–cancer) and respiratory drugs. Over the last two years GRL has introduced 12 new formulations and discontinued 4 products. These products have been the key drivers of topline growth. It's main products include Deriphyllin (for bronchitis), Dulcolax (laxatives), Primolut N and Proluton (both for hormonal imbalances). All these brands are within the top 250 brands of ORG and contribute over 25% to the company's turnover.

The share quotes at a price of Rs 612 which implies an earning multiple of 15.7 times. The current earning multiple is almost half the multiple at what the stock quoted last year.


Equitymaster requests your view! Post a comment on "German Remedies: Impressive results, attractive valuation". Click here!

  

More Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

Eris Lifesciences Limited (IPO)

Jun 15, 2017

Exposure to high margin specialty products offers promising growth prospects.

More Views on News

Most Popular

These Dividend Stocks Could Boost Your Returns Better Than You Can Imagine(Profit Hunter)

May 7, 2019

The art of dividend investing is a lot more than investing in companies with high dividend payouts or stocks with high dividend yields...

3 Indian Stocks Replicating Amazon's Successful Strategy(The 5 Minute Wrapup)

May 10, 2019

The one critical element that has made Amazon a force to reckon with...

A Simple Checklist for Picking Great Dividend Stocks(Profit Hunter)

May 9, 2019

A filtered, neat list of high-dividend stocks with all this dirty work already done for you.

My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

May 16, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

A 10-Bagger in Just 6 Years! The Rebirth of India Will Create More Big Winners Like This(The 5 Minute Wrapup)

May 7, 2019

How a niche tech startup battled all odds to eventually become a 10 bagger.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

TRACK GERMAN REMEDIES

  • Track your investment in GERMAN REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MARKET STATS